Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis. - Wikidata - awgldk - TriplyDB

Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis.

Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis.

http://www.wikidata.org/entity/Q33383677

about

Clinical indications for thrombopoietin and thrombopoietin-receptor agonists The pathophysiology of thrombocytopenia in chronic liver disease Diagnosis of cirrhosis and portal hypertension: imaging, non-invasive markers of fibrosis and liver biopsy.Rifaximin improves thrombocytopenia in patients with alcoholic cirrhosis in association with reduction of endotoxaemia.Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy.Effect of splenectomy on platelets associated antibodies in hepatitis C patients with thrombocytopenia.Prevalence of cirrhosis in patients with thrombocytopenia who receive bone marrow biopsy.Romiplostim in the management of thrombocytopenia in a patient with autoimmune hepatitis.Eltrombopag in patients with chronic liver disease.Abnormal platelet kinetics are detected before the occurrence of thrombocytopaenia in HBV-related liver disease.The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia.Kasabach-Merritt phenomenon in an adult man with a tufted angioma and cirrhosis responding to radiation, bevacizumab, and prednisone.Management of thrombocytopenia in advanced liver disease Hospital-acquired thrombocytopenia.Lymphopenia in Patients with Single-ventricle Heart Disease after the Fontan Operation.Transient Elastography for Spleen Stiffness Measurement in Patients With Cirrhosis: Role in Degree of Thrombocytopenia.Hepatitis B infection is associated with an increased incidence of thrombocytopenia in healthy adults without cirrhosis.Thrombocytopenia in chronic liver disease.IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection Importance of hepatitis C virus-associated insulin resistance: therapeutic strategies for insulin sensitization Iron deficiency anemia in chronic liver disease: etiopathogenesis, diagnosis and treatment.The role of clinically significant portal hypertension in hepatic resection for hepatocellular carcinoma patients: a propensity score matching analysis Hepatocellular carcinoma in cirrhotic patients with portal hypertension: is liver resection always contraindicated?Hypersplenism in liver disease and SLE revisited: current evidence supports an active rather than passive process.The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test.Characteristics and outcomes of neutropenia after orthotopic liver transplantation.Noninvasive methods for prediction of esophageal varices in pediatric patients with portal hypertension Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C.Abnormal hematological indices in cirrhosis.Screening of differentially expressed protein kinases in bone marrow endothelial cells and the protective effects of the p38a inhibitor SB203580 on bone marrow in liver fibrosis.Immune dysfunction in cirrhosis.Big spleens and hypersplenism: fix it or forget it?Portal hypertensive gastropathy: A systematic review of the pathophysiology, clinical presentation, natural history and therapy.The Management of Autoimmune Hepatitis Patients with Decompensated Cirrhosis: Real-World Experience and a Comprehensive Review.An unusual cause of anemia in cirrhosis: spur cell anemia, a case report with review of literature.Perioperative safety analysis of transcatheter arterial chemoembolization for hepatocellular carcinoma patients with preprocedural leukopenia or thrombocytopenia.Risk Factors and Outcomes of De Novo Cancers (Excluding Nonmelanoma Skin Cancer) After Liver Transplantation for Primary Sclerosing Cholangitis.High post-treatment absolute monocyte count predicted hepatocellular carcinoma risk in HCV patients who failed peginterferon/ribavirin therapy.Hepatic encephalopathy is related to anemia and fat-free mass depletion in liver transplant candidates with cirrhosis.Efficacy of Repeated Lusutrombopag Administration for Thrombocytopenia in a Patient Scheduled for Invasive Hepatocellular Carcinoma Treatment.

P2860

Q24601161-9833F6D2-3ACB-4FEC-B7AC-CFF50468A188 Q26749277-1617D3D1-CDDE-4F35-883E-3476BEFE48DE Q30355947-CDAEBBFE-F4FE-4672-AC41-9DE4D94593A2 Q33398338-FA2FCB84-4FFF-4B7E-9868-634992BC2D3F Q33400529-640CC05E-BDDC-4D62-87B5-3765B6944C29 Q33401584-FEF29D33-EA5E-40C0-ACEB-85953BA33781 Q33402491-187FEE87-490B-4EE5-9031-104A4FC7CA08 Q33402513-A1673BA3-A064-4CFD-9D06-D8F7A5368527 Q33406181-B7404B1F-11EB-48AF-A3EC-4B69F81CD14E Q33413800-590CC470-AD70-414C-BF3F-528249B5714A Q33414386-332B15CA-3E68-4376-BEE8-0FC74EE0EB01 Q33414391-1C060AF6-93FB-4FE3-AA43-7BDEF0DC6E82 Q33417667-B38C9011-FF93-4834-AC4D-CAC112238C36 Q33419312-BA7BB5D9-B2B3-497A-A0BC-1F887E0BD7FD Q33427432-E4B7C402-1E94-46F5-9148-48E82BCD1CEF Q33433589-3D9FED45-36A4-4026-B92E-1476E882A9A9 Q33436901-D20477D3-9F00-45D0-8C12-01ADA8505969 Q33436905-F7B72281-F7A7-4890-9C3C-8C3476F4ABAB Q33586624-7916A939-D7B9-4B06-B445-6AF00E3B2592 Q33812148-C0A570C8-A854-4F1B-A995-4CC9B7E46FDD Q33822956-3FF006DE-EA1E-4B67-AB7D-4F8B29A951B0 Q35441132-2AEFAA85-8D41-4779-B7C9-ABF79C9597DB Q35606817-E9B9F92C-415C-4061-BA33-2E94478AFCFD Q35920464-8F411A61-F810-473D-9DED-62FBACF12BD6 Q35928746-1EEA2D6B-29C2-4246-A580-E9C799E9D4DD Q36515588-7446E43F-49E5-4A02-8543-5F93B97BFABB Q36759214-E758F941-9122-4561-A160-CD02BB208506 Q37086216-37DC3B1E-CAF5-478F-BB42-699801E84AE5 Q37291711-3FEAEFC3-27EC-4C0B-9DBA-1F9ADF93B63B Q37403573-8640EDD0-A658-40EA-9A35-C09A67CA1857 Q38195835-BDF6C34F-A836-42F8-AFE4-061A8A9A39B1 Q38259960-8FE9AA0A-F708-4DB6-A2AC-4A31923BFA46 Q38726165-E98611F4-1AF0-45BA-A4A2-C575F74DAC76 Q38925324-EB6CA803-1397-440F-ABEE-713D862ECB3B Q39022979-2CF046E5-E031-4113-8DC2-318F49778B91 Q40091865-31F25234-93CA-4B6B-B0E3-D8FF08CCDF4B Q40302905-EA7FC7BB-22F1-4E79-A7FB-5D94BBD8EB6D Q40873258-F65922A6-57F8-4920-B578-F73BE96ACC4B Q43679416-EA9E13FA-0E08-4813-95D8-3A8C9FBA7D9C Q47156529-C6982744-9296-44A0-9ED9-97A1788D3282

P2860

Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis.

http://www.wikidata.org/entity/Q33383677

description

2009 nî lūn-bûn

@nan

2009 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մարտին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Incidence, prevalence, and cli ...... ices in compensated cirrhosis.

@ast

Incidence, prevalence, and cli ...... ices in compensated cirrhosis.

@en

type

label

Incidence, prevalence, and cli ...... ices in compensated cirrhosis.

@ast

Incidence, prevalence, and cli ...... ices in compensated cirrhosis.

@en

prefLabel

Incidence, prevalence, and cli ...... ices in compensated cirrhosis.

@ast

Incidence, prevalence, and cli ...... ices in compensated cirrhosis.

@en

P1433

Q33383677-1794407E-1A03-4565-BF3D-0E834BCFBC30

P1476

Q33383677-A57CD2AC-DA72-4D10-B24F-48072A730453

P2093

Q33383677-06A72D52-143B-4492-BF7E-533E6E2CAF2B

Q33383677-077E363F-D195-4419-9BB7-E518A35120A8

Q33383677-24BCF0E3-546B-4D57-A20D-A21F64B5F012

Q33383677-36768DE0-4DDB-4F43-848E-B3323F8F5CD9

Q33383677-3ABD4B52-8A77-4554-B054-CE410E51FC8E

Q33383677-49D94CF8-DF04-403C-BA02-0ACD4422FBE4

Q33383677-5DFBEF5D-FF22-435B-8F99-73C88BBDA1C4

Q33383677-6C1F7824-87F8-422B-96AE-A21B2DD512A8

Q33383677-8237B570-84FA-4AB9-94C9-EA6757FF6558

Q33383677-9A03AD54-81D5-4284-BEC3-6C8ACFBF5F37

P2860

Q33383677-08D5DA63-291E-4EC2-9554-035EC1348A8A

Q33383677-127D38F1-9FAE-4CF9-9EEB-1A496F17B4AF

Q33383677-1B156C14-E5BA-462F-B571-4E4EE54ABF61

Q33383677-30F9339F-BF7B-4A3B-8FD0-370C2B4EE5CE

Q33383677-3773650B-C8FF-435B-B926-B7E828167874

Q33383677-39CF2936-3BE7-4746-B3DC-406CA80CCEDF

Q33383677-3B3ED733-6F87-4A35-97F2-4CD2E9697867

Q33383677-4D50E10F-85A7-48CA-BE01-6F0E3465CE81

Q33383677-5B9F88DD-CEA6-41FC-93C1-2912DF1CA3FA

Q33383677-5CD2D4EA-8217-46D9-9661-057E8D15F4E0

P304

Q33383677-E7AA9700-4C14-409E-9817-6CF7F9F53342

P31

Q33383677-FBEE0D94-6D8B-4AA7-B33A-817A52EB5F0B

P356

Q33383677-34D38922-54FB-4F2B-B787-E2CF6FC44CB9

P407

Q33383677-BAC1E243-EEFB-4C73-8676-C20DEE3FFB4A

P433

Q33383677-67B6ABD4-AC37-4F2C-A1EB-790325AD7EE6

P478

Q33383677-174382CF-67CF-4698-9D55-E5835B1E12C4

P50

Q33383677-A8BDF1F6-8F83-4ACC-A1EF-37B305676E22

Q33383677-B667FBB9-0A02-4DF0-84A8-EB854EB5EBD1

P577

Q33383677-E3B2FA86-5DC7-4500-A9EC-7A1E329CF5A9

P698

Q33383677-A7F662D2-C8B5-433F-A6EA-3EED518AD9CA

P932

Q33383677-ACF78E49-40AB-4B6C-B7FC-5F0E1F670403

P356

J.CGH.2009.02.021

P1433

Clinical Gastroenterology and Hepatology

P1476

Incidence, prevalence, and cli ...... ices in compensated cirrhosis.

@en

P2093

Amir A Qamar

http://www.w3.org/2001/XMLSchema#string

Angels Escorsell

http://www.w3.org/2001/XMLSchema#string

Cristina Ripoll

http://www.w3.org/2001/XMLSchema#string

Daniel S Matloff

http://www.w3.org/2001/XMLSchema#string

David Patch

http://www.w3.org/2001/XMLSchema#string

Gabriel Rendon

http://www.w3.org/2001/XMLSchema#string

Guadalupe Garcia-Tsao

http://www.w3.org/2001/XMLSchema#string

Jaime Bosch

http://www.w3.org/2001/XMLSchema#string

Norman D Grace

http://www.w3.org/2001/XMLSchema#string

Portal Hypertension Collaborative Group

http://www.w3.org/2001/XMLSchema#string

P2860

Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease.

Thrombocytopenia in liver disease.

The effect of portacaval shunt on thrombocytopenia associated with portal hypertension.

Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosis.

Correction of hypersplenism following distal splenorenal shunt.

Splenic influences on the blood in chronic liver disease.

Effect of operations for variceal hemorrhage on hypersplenism.

Effect of portacaval anastomosis on hypersplenism.

The effect of the distal splenorenal shunt on hypersplenism.

P304

689-695

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CGH.2009.02.021

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Juan Carlos García-Pagan

Andrew K Burroughs

P577

2009-03-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19281860

http://www.w3.org/2001/XMLSchema#string

P932

4545534

http://www.w3.org/2001/XMLSchema#string